Applied Therapeutics Stock Plummets 73%. The FDA Delivers This Crushing Blow. - Barron's
Barrons ยท 475 days
High Materiality9/10
AI Summary
Applied Therapeutics' stock plunged 73% after FDA declined drug approval. The FDA cited deficiencies in the clinical application of govorestat. The company plans to address FDA concerns moving forward. Previous year-to-date gains of 135% now reversed post announcement. Loss of $730 million in valuation highlights the setback.
Sentiment Rationale
The direct refusal by the FDA greatly diminishes investor confidence, similar to past FDA rejections causing significant stock drops.
Trading Thesis
The immediate price reaction indicates a temporary market sentiment, as outcomes may change with future FDA discussions.
Market-Moving
- Applied Therapeutics' stock plunged 73% after FDA declined drug approval.
- The FDA cited deficiencies in the clinical application of govorestat.
- The company plans to address FDA concerns moving forward.
Key Facts
- Applied Therapeutics' stock plunged 73% after FDA declined drug approval.
- The FDA cited deficiencies in the clinical application of govorestat.
- The company plans to address FDA concerns moving forward.
- Previous year-to-date gains of 135% now reversed post announcement.
- Loss of $730 million in valuation highlights the setback.
Companies Mentioned
- RUT (RUT)
Others
The FDA decision is crucial to APLT's pipeline and investor outlook on future growth.